<DOC>
	<DOCNO>NCT00426023</DOCNO>
	<brief_summary>This interventional study aim evaluate efficacy Cyclosporine eye drop treatment prevent relapse Vernal Keratoconjunctivitis ( VKC ) treat acute phase disease .</brief_summary>
	<brief_title>Cyclosporin A Eye Drop Treatment Vernal Keratoconjunctivitis</brief_title>
	<detailed_description>Vernal keratoconjunctivitis ( VKC ) severe allergic disease , characterise chronic ocular surface inflammation seasonal relapse . Active phase VKC require treatment topical steroid control inflammation corneal damage may lead impairment visual function severe ocular discomfort . To date , safe effective therapy prevent relapse control active phase VKC available . Few control trial use topical Cyclosporine A ( CsA ) treatment VKC . The present multicenter , double-masked , randomise , control clinical trial allow obtain data safety efficacy topical treatment Cyclosporine patient affect VKC . Moreover , study evaluate efficacy topical CsA preventing relapse VKC control active phase disease . It important highlight Cyclosporine eye drop currently commercially available Italy must custom-made specialized pharmacy . As VKC mostly affect young patient , influence daily life social interaction . Moreover , severe sign symptom disease result frequent ophthalmologic control , influence school activity child work day parent relevant economic cost National Health System . Comparisons : Efficacy Cyclosporine A 0.05 % eye-drops preventing VKC relapse compare standard antiallergic ( Ketotifen fumarate 0.025 % eye-drops ) treatment , efficacy Cyclosporine A 0.1 % eye-drops control acute phase compare antiinflammatory ( Desametasone 0.15 % eye drop ) treatment .</detailed_description>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patients affect VKC enrol three Centres involve project Diagnosis VKC perform basis personal family history systemic allergic disease , clinical examination ( presence conjunctival tarsal and/or limbal papilla ) presence eosinophil conjunctival scrap Contact lens wearer Patients affect ocular disease Patients subject ocular surgery precede 6 month Patients eye drop systemic treatment disease , Patients enrol experimental trial precede 6 month</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Vernal keratoconjunctivitis</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Children</keyword>
	<keyword>Clinical trial</keyword>
</DOC>